Adding a new drug to standard brain cancer treatment after radiation

Plain-English translation of NCT07215910 on ClinicalTrials.gov ↗ · Source last updated September 2026 · Translation generated August 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial is testing whether adding to the standard treatment (chemotherapy after radiation) can help people with a specific type of grade 3 brain tumor called IDH-mutated astrocytoma live longer without their cancer growing. About half of participants will receive the new medication along with standard chemotherapy, and half will receive standard chemotherapy alone. The study will compare how well each group does over time.

Grade 3 brain tumors can grow quickly and be hard to treat, and current standard treatments don't work well enough for everyone. This trial is investigating whether this medication might improve outcomes by targeting a specific mutation found in these tumors.

Do you qualify?

You likely qualify if…

you have been diagnosed with a grade 3 brain tumor (astrocytoma) that has a specific genetic mutation (IDH mutation)
you have had surgery or a biopsy to remove or sample your tumor within the last 6 months
you have not received any prior chemotherapy, radiation therapy, or other cancer treatments before enrolling
you are at least 12 years old and in reasonably good overall health
your blood cell counts and liver and kidney function are within acceptable ranges

You likely don't qualify if…

you have received any prior chemotherapy, radiation therapy, or IDH inhibitor therapy
you have evidence of cancer spread to your spine or the membranes around your brain
you are pregnant, nursing, or unwilling to use birth control during and after the study
you have certain genetic features (CDKN2A/B deletion or 1p/19q co-deletion) in your tumor cells
your blood cell counts, liver function, or kidney function are too low or too high

What participation looks like

You will first receive radiation therapy 5 days a week for about 6-7 weeks. Then, starting 4 weeks later, you will take either the new medication plus standard chemotherapy or standard chemotherapy alone for up to 12 months, in monthly cycles. Throughout the study, you will have blood tests and MRI scans to monitor your progress and check for side effects.

AI-generated summary from trial data · Aug 6, 2026 · Not medical advice

Adding a new drug to standard brain cancer treatment after radiation

What is this trial?

Do you qualify?

What participation looks like

Trial locations(121 sites)